


1 Supplemental Figures




2

3

4 **Figure S1. Generation and phenotype of CD8⁺ iTregs.**

5 Allogeneic CD8⁺ iTregs were generated *in vitro* as described in figure 1. At day 5, expression of
6 Foxp3⁺ was analyzed by flow cytometry. (A) FACS plots and graphs show %Foxp3⁺ expression
7 among WT and JAK2^{-/-} CD8⁺ cells (n=3/group). (B) %Foxp3⁺ Nrp1⁺ on day 0, 3 and 5 of iTreg
8 generation from WT and JAK2^{-/-} CD8⁺ cells (n=3/group). Student's *t*-test was used to compare
9 the data. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Data represent the mean ± SEM.

10




12

13

14 **Figure S2. Suppressive activity of CD8 iTregs *in vivo*.**

15 Lethally irradiated BALB/c mice were adoptively transferred as shown in figure 4A. Seven days
 16 after BMT, CFSE profile was shown among H2^bLy5.1⁺Teff cells. Representative %CFSE-
 17 diluted cells on gated (A) CD4⁺ and (B) CD8⁺ Teffs are shown. Data are replicate of 2
 18 independent experiments (n=9/group). A One- way ANOVA was used to compare the data. *p ≤
 19 0.05, **p ≤ 0.01, ***p ≤ 0.001 and, ****p ≤ 0.0001. Data represent the mean ± SEM.



20



21
 22
 23
 24
 25
 26
 27
 28
 29
 30

Figure S3. Cytotoxic activity of CD8⁺ iTregs *in vitro*.

Various subsets of T cells as effectors (E) were co-cultured with luciferase-expressing allogeneic P815 mastocytoma targets (T) at 37°C for 4 hrs. After incubation, luciferin was added to the culture. Bioluminescent imaging data were analyzed and quantified using Living Imager Software. **(A and C)** Luminescence images of 96-well plates showing viable tumor cell in Red. **(B and D)** Graph depicting %cytotoxic activity in different E: T ratio is shown. Student's *t*-test was used to compare % cytotoxicity. **p* ≤ 0.05, ***p* ≤ 0.01 and ****p* ≤ 0.001. Data represent the mean ± SEM.



31
 32 **Figure S4. Effects of CD8 iTregs on GVHD and GVL responses after allo-BMT.**
 33 Lethally irradiated BDF1 mice were adoptively transferred with 2×10^6 CD8⁺ iTregs, 5×10^6 WT-
 34 TCD BM, and 5×10^3 P815 mastocytoma. Three days later, 3×10^6 CD25-depleted T-cells were i.v
 35 injected to induce GVHD. Recipients were monitored for (A) tumor burden, (B) tumor mortality
 36 and (C) survival until day 60. Data are combined from 2 independent experiments (n=8-
 37 9/group). * $p \leq 0.05$. Data represent the mean \pm SEM. Log-rank (Mantel-Cox) test was used to
 38 compare the tumor mortality and survival.